|
|
PCV2 INSIGHT
Global PCV2 Trends & Herd Monitoring
|
NEWSLETTER
AUGUST 2026 |
|
|
GLOBAL · GENOTYPES
Global Genotype Shift
A decade-wide meta-analysis shows a clear shift from PCV2b toward PCV2d.
|
JAPAN · 2025
PCV2d Field Predominance
Recent Japanese surveillance identified PCV2d across all sampled farms.
|
VIETNAM · 2024
Genotype Shift Toward PCV2d
Recent field data confirm a genotype shift from PCV2b toward PCV2d in Vietnam.
|
Sources: VirusDisease · 2025 · NVAL Japan · 2025 · Vet. Res. Commun. · 2024
|
|
SPECIAL REPORT · GLOBAL
PCV2d Leads,
PCV2a Still Circulates
Recent studies show marked regional differences in PCV2 genotype distribution, supporting continued molecular surveillance.
|
 |
|
|
WHY PCV2 TESTING STILL MATTERS
Why Monitoring Still Matters
Vaccination reduces clinical disease and viral shedding but does not fully prevent infection. Antibody and viral monitoring provide complementary information on herd exposure and vaccine response. BMC Veterinary Research · 2025.11.28
|
01. Monitor Antibody Response After Vaccination
PCV2 IgG peaked at 7 weeks of age, showing how antibody levels change after vaccination.
Vaccines · 2024.11.26 →
|
02. Check MDA Before Vaccination
Maternally derived antibodies (MDA) peaked at 1–3 days after colostrum intake and then declined through day 19.
J. Vet. Med. Sci. · 2026.07.06 →
|
|
|
|
GLOBAL GENOTYPE LANDSCAPE
PCV2d Leads Worldwide
Meta-analysis · 26,200 samples · 18 countries
Meta-analysis of 26,200 samples from 18 countries showed a global shift from PCV2b to PCV2d.
VirusDisease · 2025
|
KOREA SNAPSHOT
PCV2d 81.0%
PCV2a 17.4%
PCV2 detection: 24.8%
Average detection in disease-suspect pig samples, 2021–2023.
Front. Vet. Sci. · 2025
※ Clinical sample detection rates do not equal nationwide prevalence.
|
|
|
2024–2026 GLOBAL PCV2 RESEARCH SNAPSHOT
Regional PCV2 Updates
|
VIETNAM · 2024
PCV2d 80.85% & Genotype Shift
Among 47 genomes from 2022–2023, PCV2d accounted for 80.85%, with Cap substitutions concentrated in antigenic regions.
Vet. Res. Commun. · 2024 →
|
JAPAN · 2025
PCV2d Dominates Recent Field Samples
PCV2d was identified in all seven field samples collected from seven Japanese farms in 2022–2023.
NVAL Japan · 2025 →
|
|
CHINA · 2026
PCV2d 78.89% with Cap Variation
PCV2d represented 78.89% of 379 ORF2 sequences, with frequent mutations in immunodominant Cap regions and key neutralizing epitopes.
Viruses · 2026 →
|
MEXICO · 2026
PCV2a & PCV2d Co-circulate
Among 70 ORF2 sequences, PCV2d was 72.9% and PCV2a 27.1%; seven recombinant sequences were also identified.
Vaccines · 2026 →
|
|
|
MEDIAN PCV2 DIAGNOSTICS · ANTIBODY
Serum · Indirect ELISA · Dual-antigen coating · Recombinant protein
ES-PCV-02
192 · 480 Tests/Kit
VIEW PRODUCT →
|
VDPro® SERIES · ES-PCV-02
VDPro®
PCV2 AB ELISA ver. 2.0
PCV2a & PCV2d
Antibody Monitoring
Indirect ELISA optimized for PCV2d with dual-antigen coating for PCV2a and PCV2d antibody detection.
KEY APPLICATIONS
Post-vaccination response · Herd-level antibody monitoring · PCV2a & PCV2d antibody detection
|
PERFORMANCE DATA
|
|
MEDIAN PCV2 MOLECULAR DIAGNOSTICS
PCV2 PCR Lineup
From PCV2 detection to PCV2d typing and PRRSV co-testing.
|
TARGETS
PCV2 · PCV2d
Detect PCV2 · Type PCV2d
|
VDx® PCV2 MP qPCR |
Multiplex real-time PCR for PCV2 detection and PCV2d typing in one run. |
Specimens: Whole blood, serum, semen and tissue homogenates
Pack: 96 Tests/Box |
VIEW PRODUCT → |
|
|
TARGETS
PCV2
Detect PCV2 DNA
|
VDx® PCV2 qPCR |
TaqMan-based real-time PCR for PCV2 DNA detection. |
Specimens: Whole blood, serum, semen and tissue homogenates
Pack: 96 Tests/Box · APQA approved |
VIEW PRODUCT → |
|
|
TARGETS
PRRSV-1 · PRRSV-2 · PCV2
Type PRRSV-1/2 · Detect PCV2
|
VDx® PRRSV/PCV2 qRT-PCR |
Multiplex qRT-PCR for PRRSV-1/2 typing with simultaneous PCV2 detection. |
Specimens: Whole blood, serum, semen and tissue homogenates
Pack: 96 Tests/Box · APQA approved |
VIEW PRODUCT → |
|
|
TARGETS
PCV2 ORF2 · 493 bp
Amplify PCV2 ORF2
|
VDx® PCV2 ORF2 PCR |
Conventional PCR targeting a 493 bp region of PCV2 ORF2. |
Specimens: Whole blood, serum, semen and tissue homogenates
Pack: 50 Tests/Box · APQA approved |
VIEW PRODUCT → |
|
VIEW ALL PCV2 DIAGNOSTICS →
|
|
FOLLOW MEDIAN DIAGNOSTICS
|
MEDIAN Diagnostics Inc.
878, Sunhwan-daero, Dongnae-myeon, Chuncheon-si, Gangwon-do, Korea
Tel. +82-33-244-0100 Fax. +82-33-244-4634
median@mediandx.com |
SEOUL OFFICE
C-1114, SK V1 GL Metrocity, 128, Beobwon-ro, Songpa-gu, Seoul, Korea
Tel. +82-2-3401-0110 |
Copyright © 2026 MEDIAN Diagnostics Inc. All Rights Reserved. |
|
